8-K
filed August 21, 2023, 7:59 PM ET
ticker BCTX
CIK 0001610820
other material
confidence high
sentiment neutral
materiality 0.70
BriaCell shareholders approve spinout of BriaPro Therapeutics with 98.9% support
BriaCell Therapeutics Corp.
- Shareholders approved Arrangement to spin out BriaPro Therapeutics (Bria-TILsRx, PKCδ inhibitors) with 98.92% votes.
- SpinCo will be a 2/3 owned subsidiary of BriaCell; each share gets one SpinCo share and one new BriaCell share.
- Closing expected on/around Aug 31, 2023, subject to final court approval on Aug 25 and regulatory approvals.
- SpinCo Option Plan approved (89.70% votes); August 2022 option grant ratified (99.10% votes).
- BriaCell remains listed on NASDAQ/TSX; SpinCo will become an unlisted reporting issuer in Canada.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BriaCell Therapeutics Corp. shareholders approved Approval of the SpinCo omnibus equity incentive plan at the 2023-08-18 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-08-18
Exact text from the filing
Proposal 2. At the Meeting, a majority of the votes cast by shareholders of the Company on this proposal, approved the Spinco omnibus equity incentive plan (the “SpinCo Incentive Plan”). The result of the votes to approve the SpinCo Incentive Plan was as follows: For Against Abstain Broker Non-Votes 6,179,448 705,709 4,004 1
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BriaCell Therapeutics Corp. shareholders approved Ratification and confirmation of grant of options to officers under former stock option plan at the 2023-08-18 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-08-18
Exact text from the filing
Proposal 3. At the Meeting, a majority of the votes cast by shareholders of the Company on this proposal, upon approving the SpinCo Incentive Plan, ratified, confirmed and approved a grant of an aggregate of 180,100 options to acquire shares of the Company on August 2, 2022, granted under the Company’s stock option plan, which was superseded by the Company’s omnibus equity incentive plan, to the officers listed in the table below, on August 2, 2022 (the “ Award ”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BriaCell Therapeutics Corp. shareholders approved Approval of the arrangement agreement and plan of arrangement with SpinCo at the 2023-08-18 meeting.
- Proposal
- merger approval
- Outcome
- passed
- Meeting
- 2023-08-18
Exact text from the filing
Proposal 1. At the Meeting, not less than two-thirds of the votes cast by shareholders of the Company cast on this proposal, approved the arrangement agreement), between the Company and BriaPro Therapeutics Corp. (“SpinCo”) and the statutory plan of arrangement pursuant to Section 288 of the Business Corporations Act (British Columbia). The result of the votes to approve the arrangement agreement and the plan of arrangement was as follows: For Against Abstain Broker Non-Votes 6,814,983 71,082 3,097 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.